Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biolinerx Ltd ADR (NQ: BLRX )

0.5702 -0.0428 (-6.98%)
Streaming Delayed Price Updated: 12:37 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biolinerx Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Why BioLineRx Shares Are Getting Obliterated Monday
BioLine RX Ltd - ADR (NASDAQ: BLRX) shares are trading lower by 32.21% to $1.06 Monday morning after the company announced a $15 million registered direct offering. What Else? 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
Recap: BioLine Rx Q2 Earnings
  BioLine Rx (NASDAQ:BLRX) reported its Q2 earnings results on Tuesday, August 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: BioLine Rx Q1 Earnings
BioLine Rx (NASDAQ:BLRX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: BioLine Rx Q4 Earnings
BioLine Rx (NASDAQ:BLRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
BioLineRx Seeks FDA Nod For Stem Cell Mobilization Candidate
BioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous... 
Via Benzinga
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development... 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Performance Shipping Inc. (NASDAQ: PSHG) rose 41.7% to $ 0.94 in pre-market trading. Performance Shipping shares dipped around 64% on Friday after the company announced the pricing of an... 
Via Benzinga
Earnings Preview: BioLine Rx
BioLine Rx (NASDAQ:BLRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
BioLine Rx's Earnings Outlook
BioLine Rx (NASDAQ:BLRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million. 
Via Benzinga
Banned diamonds
Pres. Biden plans to rap the oil reserve to lower gasoline prices by a million barrels per day for 180 mn barrels. 
Via Talk Markets
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
Earnings Scheduled For March 16, 2022
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena... 
Via Benzinga
A Receding tide
Sanofi and GlaxoSmithKline have developed a new Covid-19 vaccine which they claim is 100% efficient. 
Via Talk Markets
A News Blizzard
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
World Markets News for Wednesday
Gold and the Euro are up as the greenback loses traction. 
Via Talk Markets
World Markets News
Today oil and gas inventories were seen as higher than expected while potential prices fell, both bullish. 
Via Talk Markets
Chopped Stocks
The day's theme is sell tech and buy banks. 
Via Talk Markets
More Serious Matters
Wall Street fell on new worries about inflation and a drop in retail sales levels. 
Via Talk Markets
Happy New Year - Sunday Edition
Starting a new year - we look at tech, pharma and mining stocks and their goings-on. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers OptiNose (NASDAQ:OPTN) shares mov... 
Via Benzinga
Dreaming Of A Red Christmas
The stock market is reacting with lots of selling to the weekend's news. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Genfit (NASDAQ:GNFT) stock moved upwards by 38.55% to $4.6 during Friday's pre-market session. The market value of their outstanding shares is at $210.4... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.